
1. parasite. 2016;23:60. doi: 10.1051/parasite/2016069. epub 2016 dec 22.

polymorphisms k13, pfcrt, pfmdr1, pfdhfr, pfdhps parasites isolated
from symptomatic malaria patients burkina faso.

somé af(1), sorgho h(2), zongo i(1), bazié t(1), nikiéma f(1), sawadogo a(1),
zongo m(1), compaoré yd(1), ouédraogo jb(1).

author information: 
(1)institut de recherche en sciences de la santé, direction régionale de l'ouest,
399 avenue de la liberté, 01 bp 545, bobo-dioulasso 01, burkina faso.
(2)institut de recherche en sciences de la santé, unité de recherche clinique de 
nanoro, bp 218 ouaga cms 11, burkina faso.

background: emergence resistance artemisinin derivatives western
cambodia threatening revert recent advances made toward global malaria 
control elimination. known resistance-mediating polymorphisms k13,
pfcrt, pfmdr1, pfdhfr, pfdhps genes greatest importance monitoring
the spread antimalarial drug resistance.
methods: samples present study collected 244 patients with
uncomplicated malaria health centers bobo-dioulasso, burkina faso. blood
sample collected filter paper subject received treatment.
the parasite dna extracted amplified polymerase chain reaction
(pcr) evaluate prevalence polymorphism pfcrtk76t, pfmdr1 (n86y,
y184f), pfdhps (a437g, k540e). k13 gene polymorphism analyzed by
nested pcr followed sequencing.
results: overall results showed 2.26% (5/221) k13 synonymous mutant
alleles (two c469c, one y493y, one g496g, one v589v), 24.78%, 19.58%, 68.75%,
60.9%, 53.7%, 63.8%, 64.28%, respectively, mutant pfcrt 76t, pfmdr1-86y, 
pfmdr1-184f, pfdhfr51i, pfdhfr59r, pfdhfr108n, pfdhps 437g. report
any mutation codon 540 pfdhps.
conclusion: results provide baseline prevalence known drug resistance
polymorphisms suggest artemisinin combination therapies may retain good 
efficacy treatment uncomplicated malaria burkina faso.

© a.f. somé et al., published edp sciences, 2016.

doi: 10.1051/parasite/2016069 
pmcid: pmc5178381
pmid: 28004634  [indexed medline]

